Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-17T10:06:20.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science: (July 2008)

Published online by Cambridge University Press:  01 October 2008

R Sutherland
R Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Information
Breast Cancer Online , Volume 11 , Issue 10 , October 2008 , e20
Copyright
Copyright © Cambridge University Press 2008

References

1.Akil, N, Yasmeen, A, Kassab, A, Ghabreau, L, Darnel, AD, Al Moustafa, AE. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 2008; 99: 404–407.CrossRefGoogle ScholarPubMed
2.Anders, CK, Hsu, DS, Broadwater, G, Acharya, CR, Foekens, JA, Zhang, Y, Wang, YX, Marcom, PK, Marks, JR, Febbo, PG, Nevins, JR, Potti, A, Blackwell, KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324–3330.CrossRefGoogle ScholarPubMed
3.Barnett, GC, Shah, M, Redman, K, Easton, DF, Ponder, BAJ, Pharoah, PDP. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26: 3310–3316.CrossRefGoogle ScholarPubMed
4.Bauerschmitz, GJ, Ranki, T, Kangasniemi, L, Ribacka, C, Eriksson, M, Porten, M, Herrmann, I, Ristimaki, A, Virkkunen, P, Tarkkanen, M, Hakkarainen, T, Kanerva, A, Rein, D, Pesonen, S, Hemminki, A. Tissue-specific promoters active in CD44(+)CD24(−/low) breast cancer cells. Cancer Res 2008; 68: 5533–5539.CrossRefGoogle Scholar
5.Belkhiri, A, Dar, AA, Peng, D, Razvi, MH, Rinehart, C, Arteaga, CL, El-Rifai, W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 2008; 14: 4564–4571.CrossRefGoogle ScholarPubMed
6.Crandall, CJ, Guan, M, Laughlin, GA, Ursin, GA, Stanczyk, FZ, Ingles, SA, Barrett-Connor, E, Greendale, GA. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2008; 17: 1674–1681.CrossRefGoogle ScholarPubMed
7.Diergaarde, B, Potter, JD, Jupe, ER, Manjeshwar, S, Shimasaki, CD, Pugh, TW, DeFreese, DC, Gramling, BA, Evans, I, White, E. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 1751–1759.CrossRefGoogle ScholarPubMed
8.Elsheikh, SE, Green, AR, Rakha, EA, Samaka, RM, Ammar, AA, Powe, D, Reis-Filho, JS, Ellis, IO. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008; 99: 327–334.CrossRefGoogle ScholarPubMed
9.Fagerholm, R, Hofstetter, B, Tommiska, J, Aaltonen, K, Vrtel, R, Syrjakoski, K, Kallioniemi, A, Kilpivaara, O, Mannermaa, A, Kosma, VM, Uusitupa, M, Eskelinen, M, Kataja, V, Aittomakii, K, von Smitten, K, Heikkila, P, Lukas, J, Holli, K, Bartkova, J, Blomqvist, C, Bartek, J, Nevanlinna, H. NAD(P)H: quinone oxidoreductase 1 NQO1(star)2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40: 844–853.CrossRefGoogle Scholar
10.Fleury, L, Gerus, M, Lavigne, AC, Richard-Foy, H, Bystricky, K. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 2008; 27: 4075–4085.CrossRefGoogle ScholarPubMed
11.Gail, MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037–1041.CrossRefGoogle ScholarPubMed
12.Ghoussaini, M, Song, HL, Koessler, T, Al Olama, AA, Kote-Jarai, Z, Driver, KE, Pooley, KA, Ramus, SJ, Kjaer, SK, Hogdall, E, DiCioccio, RA, Whittemore, AS, Gayther, SA, Giles, GG, Guy, M, Edwards, SM, Morrison, J, Donovan, JL, Hamdy, FC, Dearnaley, DP, Ardern-Jones, AT, Hall, AL, O’Brien, LT, Gehr-Swain, BN, Wilkinson, RA, Brown, PM, Hopper, JL, Neal, DE, Pharoah, PDP, Ponder, BAJ, Eeles, RA, Easton, DF, Dunning, AM. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008; 100: 962–966.CrossRefGoogle ScholarPubMed
13.Golouh, R, Cufer, T, Sadikov, A, Nussdorfer, P, Usher, PA, Brunner, N, Schmitt, M, Lesche, R, Maier, S, Timmermans, M, Foekens, JA, Martens, JWM. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110: 317–326.CrossRefGoogle ScholarPubMed
14.Hayes, MJ, Thomas, D, Emmons, A, Giordano, TJ, Kleer, CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008; 14: 4038–4044.CrossRefGoogle ScholarPubMed
15.Iakovlev, VV, Arneson, NCR, Wong, V, Wang, CJ, Leung, S, Iakovleva, G, Warren, K, Pintilie, M, Done, SJ. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 2008; 14: 4446–4454.CrossRefGoogle ScholarPubMed
16.Jiang, WQ, Zhu, ZJ, Thompson, HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008; 68: 5492–5499.CrossRefGoogle Scholar
17.Kondo, N, Toyama, T, Sugiura, H, Fujii, Y, Yamashita, H. miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res 2008; 68: 5004–5008.CrossRefGoogle ScholarPubMed
18.Kovalchuk, O, Filkowski, J, Meservy, J, Iinytskyy, Y, Tryndyak, VP, Chekhun, VF, Pogribny, IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152–2159.CrossRefGoogle ScholarPubMed
19.Lee, CW, Raskett, CM, Prudovsky, I, Altieri, DC. Molecular dependence of estrogen receptor-negative breast cancer on a Notch-survivin signaling axis. Cancer Res 2008; 68: 5273–5281.CrossRefGoogle ScholarPubMed
20.Lee-Hoeflich, ST, Crocker, L, Yao, E, Pham, T, Munroe, X, Hoeflich, KP, Sliwkowski, MX, Stern, HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878–5887.CrossRefGoogle ScholarPubMed
21.Lord, SJ, Bernstein, L, Johnson, KA, Malone, KE, McDonald, JA, Marchbanks, PA, Simon, MS, Strom, BL, Press, MF, Folger, SG, Burkman, RT, Deapen, D, Spirtas, R, Ursin, G. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 1723–1730.CrossRefGoogle ScholarPubMed
22.Nam, DH, Jeon, HM, Kim, S, Kim, MH, Lee, YJ, Lee, MS, Kim, H, Joo, KM, Lee, DS, Price, JE, Bang, SI, Park, WY. Activation of Notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 2008; 14: 4059–4066.CrossRefGoogle Scholar
23.O’Brien, C, Cavet, G, Pandita, A, Hu, XL, Haydu, L, Mohan, S, Toy, K, Rivers, CS, Modrusan, Z, Amler, LC, Lackner, MR. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008; 68: 5380–5389.CrossRefGoogle ScholarPubMed
24.Rizzo, P, Miao, H, D’Souza, G, Osipo, C, Yun, J, Zhao, HP, Mascarenhas, J, Wyatt, D, Antico, G, Hao, L, Yao, K, Rajan, P, Hicks, C, Siziopikou, K, Selvaggi, S, Bashir, A, Bhandari, D, Marchese, A, Lendahl, U, Qin, JZ, Tonetti, DA, Albain, K, Nickoloff, BJ, Miele, L. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68: 5226–5235.CrossRefGoogle ScholarPubMed
25.Schmidt, M, Bohm, D, von Torne, C, Steiner, E, Puhl, A, Pilch, H, Lehr, HA, Hengstler, JG, Kolbl, H, Gehrmann, M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405–5413.CrossRefGoogle Scholar
26.Steelman, LS, Navolanic, PM, Sokolosky, ML, Taylor, JR, Lehmann, BD, Chappell, WH, Abrams, SL, Wong, EWT, Stadelman, KM, Terrian, DM, Leslie, NR, Martelli, AM, Stivala, F, Libra, M, Franklin, RA, McCubrey, JA. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008; 27: 4086–4095.CrossRefGoogle ScholarPubMed
27.Vasiljeva, O, Korovin, M, Gajda, M, Brodoefel, H, Bojic, L, Kruger, A, Schurigt, U, Sevenich, L, Turk, B, Peters, C, Reinheckel, T. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008; 27: 4191–4199.CrossRefGoogle ScholarPubMed
28.Wang, Y, Dean, JL, Millar, EKA, Tran, TH, McNeil, CM, Burd, CJ, Henshall, SM, Utama, FE, Witkiewicz, A, Rui, H, Sutherland, RL, Knudsen, KE, Knudsen, ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68: 5628–5638.CrossRefGoogle ScholarPubMed
29.Zhang, D, Shimizu, T, Araki, N, Hirota, T, Yoshie, M, Ogawa, K, Nakagata, N, Takeya, M, Saya, H. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene 2008; 27: 4305–4314.CrossRefGoogle Scholar